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Inducible nitric oxide synthase (iNOS)
expression upregulates p21 and inhibits
vascular smooth muscle cell proliferation
through p42/44 mitogen-activated protein
kinase activation and independent of p53
and cyclic guanosine monophosphate
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Objective: Overexpression of the inducible nitric oxide synthase (iNOS) gene inhibits
neointimal hyperplasia after arterial injury. The purpose of this study was to examine
the mechanism by which nitric oxide (NO) inhibits vascular smooth muscle cell (VSMC)
proliferation, specifically focusing on signaling pathways known to be activated by NO,
including cyclic guanosine monophosphate (cGMP), p53, and p42/44 mitogen-activat-
ed protein kinase (MAPK).
Methods and Results: VSMCs that were subjected to iNOS gene transfer demonstrated a
reduction in proliferation (80%) that was associated with a marked increase in p21 expres-
sion. The antiproliferative and p21 stimulatory effects of NO were not suppressed by the
soluble guanylate cyclase inhibitor ODQ, implicating cGMP-independent signaling. The
role of p53 in NO-mediated upregulation of p21 and inhibition of proliferation was eval-
uated using p53 –/– VSMCs. A similar reduction in cellular proliferation and upregula-
tion of p21 expression were achieved with iNOS gene transfer as well as treatment with
the NO-donor S-nitroso-N-acetylpenicillamine (SNAP), demonstrating the p53-indepen-
dent nature of these NO-mediated pathways. The transfer of the iNOS gene activated the
p42/44 MAPK, and inhibition of this MAPK pathway with PD98059 partially blocked
the antiproliferative effects of NO and completely inhibited the p21 stimulatory effects of
NO. For confirmation that iNOS overexpression upregulated p21 in vivo, injured rat
carotid arteries were infected with an adenoviral vector carrying the iNOS gene and
demonstrated a marked upregulation of p21 expression at three days. However, the abil-
ity of NO to inhibit VSMC proliferation does not solely depend on p21 upregulation since
the NO-donor SNAP-inhibited VSMC proliferation in p21 –/– VSMCs.
Conclusion: Nitric oxide inhibits VSMC proliferation in association with the upregula-
tion of p21; both occur independent of p53 and cGMP while being partially mediated
through the p42/44 MAPK signaling cascade. This represents one potential mechanism
by which NO inhibits VSMC proliferation. (J Vasc Surg 2000;31:1214-28.)
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Intimal hyperplasia resulting from vascular
injury initiated by procedures such as percutaneous
transluminal angioplasty or surgical bypass grafting
continues to limit the success of these therapeutic
interventions. Many pharmacologic agents, includ-
ing antithrombotics, antiplatelet agents, and
angiotensin-converting enzyme inhibitors, as well
as intraluminal irradiation, have been used in an
attempt to attenuate this injury response.1 Nitric
oxide (NO) has emerged as a potent inhibitor of
intimal hyperplasia, focusing attention on NO-
based approaches to inhibit injury-induced intimal
hyperplasia. Administration of arginine, the sub-
strate for NO synthesis, decreases intimal hyperpla-
sia in injured arteries2 and vein bypass grafts.3 The
delivery of NO by NO-releasing molecules,4 inhala-
tion,5 and gene transfer6,7 has also been shown to
dramatically inhibit injury-induced intimal hyper-
plasia.
We and others have used NO synthase gene
transfer for local NO delivery to inhibit intimal
hyperplasia.6-10 This approach takes advantage of
the capacity of NO to inhibit the vascular prolifera-
tive response through the sustained, local produc-
tion of NO afforded by expression of nitric oxide
synthase (NOS) only at the site of injury. Intimal
hyperplasia has been significantly inhibited in animal
models of arterial injury with gene transfer using
either endothelial NOS (type 3)6 or inducible nitric
oxide synthase (iNOS) (type 2).7 In our laboratory,
iNOS gene transfer has been applied successfully to
reduce allograft vasculopathy in rodent models8 and
balloon-injury–induced intimal hyperplasia in both
rat and pig models.7 Gene therapy with iNOS using
low viral titers was sufficient to effectuate the inhibi-
tion of intimal hyperplasia and suggests that iNOS
gene transfer holds promise as a clinical therapy.
Even in light of the success of NO-based
approaches and specifically NOS gene transfer, the
mechanisms by which NO inhibits intimal hyperplasia
are still poorly understood. Proposed mechanisms
include the ability of NO to inhibit platelet aggrega-
tion, leukocyte chemotaxis, vascular smooth muscle
cell (VSMC) proliferation and migration, and to pro-
mote endothelial cell growth.11 Of these mechanisms,
the antiproliferative effect of NO on VSMCs has been
proposed as one of the most important. Furthermore,
there is evidence that endogenous sources of NO are
important for the suppression of VSMC proliferation
in normal blood vessel hemostasis12 and after injury.7
In this study, we sought to determine the signaling
pathways involved in the inhibition of VSMC prolif-
eration after NO exposure.
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EXPERIMENTAL PROCEDURES
Adenoviral vectors. The human iNOS comple-
mentary DNA (cDNA) was cloned from cytokine-
stimulated human hepatocytes.13 An E1- and E3-
deleted adenoviral vector carrying the human iNOS
cDNA (AdiNOS) was designed and constructed as
previously described.7,8 The titer of AdiNOS was
approximately 109 plaque-forming units (PFU)/mL,
and the β-galactosidase gene (AdlacZ) was approxi-
mately 1011 PFU/mL.
Cell culture. Aortic VSMCs were cultured from
explanted thoracic aortae as previously described14
from Sprague-Dawley rats (Harlan, Indianapolis, Ind),
p53 –/– mice (Taconic Laboratories, Germantown,
NY), p21 –/– mice (generous gift from John Letterio,
NCI, Bethesda, Md), and wild-type C57BL/6xSV129
mice (Taconic Laboratories). Cultured cells had the
characteristic appearance of hills and valleys and were
routinely more than 95% pure by smooth muscle cell
(SMC) α-actin staining. Cells were grown in Dulbecco
modified Eagle medium (low glucose)/Ham’s F12
(1:1 vol:vol) (BioWhittaker, Walkersville, Md); supple-
mented with 10% fetal bovine serum (FBS), 100
U/mL penicillin, 100 µg/mL streptomycin, and 4
mmol/L L-glutamine; and maintained in a 37°C, 95%
air/5% carbon dioxide incubator.
Transduction of VSMCs in vitro. The VSMCs
(passages 3-8) were plated for 24 hours then serum-
starved for an additional 24 hours to induce cell cycle
arrest. The VSMCs were then infected for 2 hours at
37°C with AdlacZ or AdiNOS using a multiplicity of
infection (MOI) of 10 for the rat aortic VSMCs
(RASMCs) or two for the p53 –/– VSMCs. These
MOIs were chosen on the basis of prior experiments
demonstrating a level of nitrite (NO2–) production
that was not associated with toxicity to the VSMCs.
Immediately after infection, cells were serum starved
for an additional 24 hours. Cells were placed in
growth media containing 10% FBS for 24 hours to
stimulate proliferation. Because unstimulated VSMCs
do not possess a functional biosynthetic pathway for
the essential NOS cofactor tetrahydrobiopterin
(BH4),15,16 exogenous BH4 (10 µmol/L) was added
to all cells to optimize iNOS activity. The following
compounds were added to some of the groups: 1H-
[1,2,4]oxadiazole [4,3-a] quinoxalin-1-one (ODQ)
(Tocris Cookson, St Louis, Mo), PD 98059 (Alexis,
San Diego, Calif), and L-N5-(1-iminoethyl)-
ornithine dihydrochloride (L-NIO) (Alexis). The
accumulation of NO2– was assayed using the Griess
reaction to estimate NO synthesis after adenoviral infec-
tion.17 Cyclic guanosine monophosphate (cGMP)
release was measured with a commercially available
radioimmunoassay (NEN, Boston, Mass), after the
stabilization of the cyclic nucleotide in the super-
natant with the phosphodiesterase inhibitor 3-
isobutyl-1-methylxanthine (0.5 mmol/L; Sigma, St
Louis, Mo). Total cellular protein was quantified
using the bicinchoninic acid (BCA) protein assay
(Pierce, Rockford, Ill).
Determination of SMC proliferation in vitro.
Growth-arrested VSMCs were stimulated to prolifer-
ate with 10% FBS in the presence of 5 µCi/mL of 3H-
thymidine (NEN, Boston, Mass) for 24 hours. For
some experiments, cells were treated with S-nitroso-
N-acetylpenicillamine (SNAP),18 8-Bromo-cGMP
(Sigma), or 8-(4-Chlorophenylthio)cGMP (8-pCPT-
cGMP; BioLog, La Jolla, Calif). 3H-thymidine incor-
poration into trichloroacetic acid–precipitated DNA
was quantified by scintillation counting.
Viability. Trypan blue exclusion was analyzed by
trypsinizing (0.25%; Gibco, Grand Island, NY) the
cells and diluting the cells in a 1:4 ratio with trypan
blue (Gibco) to determine if high levels of NO were
cytotoxic to the VSMCs. All contents of the tissue
culture dish wells were analyzed so that any floating
cells or debris was not missed. Cells were counted
with a hemocytometer, and percentage viability was
calculated by dividing the number of cells excluding
trypan blue by the total number of cells.
Fluorescence-activated cell sorter (FACS)
analysis. The VSMCs were trypsinized (0.25%),
combined with the media from the respective wells,
centrifuged, washed with phosphate buffered saline
(PBS), and permeabilized with 70% ethanol for 30
minutes at 4°C. Cells were treated with deoxyri-
bonuclease–free ribonuclease (5 µg/mL; Boehringer
Mannheim, Indianapolis, Ind) for 30 minutes at
37°C and then stained with propidium iodide 
(50 µg/mL; Sigma) for FACS analysis (Becton
Dickinson FACScan Franklin Lakes, NJ) using Lysis
II cell cycle analysis software. A total of 1 × 104 cells
were counted for each sample.
DNA fragmentation analysis. After treatment,
adherent and detached cells were collected by scrap-
ing and were lysed in 20 mmol/L Tris-HCl (pH
8.0), 10 mmol/L EDTA, and 0.5% Triton-X100.
Protein concentrations of cell lysates were deter-
mined with the BCA assay. After phenol/chloro-
form (1:1) extraction, cytosolic DNA was ethanol
precipitated and dissolved in Tris-EDTA (pH 8.0)
and ribonuclease (100 µg/mL). The DNA prepara-
tions (normalized by protein concentration) were
electrophoresed on 1.2% agarose gels with ethidium
bromide. A 123-base pair DNA molecular weight
standard was used.
Western blot analysis. The VSMCs were col-
lected after 24 hours of exposure to the different
treatment groups by scraping and were resuspended
in 20 mmol/L Tris with 100 µmol/L phenyl-
methylsulfonylflouride (Sigma), 1 µmol/L leupeptin
(Sigma), and 1 µmol/L sodium orthovanadate
(Sigma). Protein was quantified with the BCA pro-
tein assay. Whole cell samples (40 µg) were subject-
ed to sodium dodecylsulfate-polyacrylamide gel
electrophoresis on 10% or 13% gels and transferred
to nitrocellulose membranes (Schleicher & Schuell,
Keene, NH) as described.19 Membranes were
hybridized with a rabbit polyclonal anti-p21 anti-
body (1:1000; Santa Cruz, Santa Cruz, Calif), with
a rabbit polyclonal anti–protein kinase G (PKG)
antibody (Calbiochem, San Diego, Calif), or for a
rabbit polyclonal anti-phospho-p42/44 or p42/44
antibody (1:1000; New England Biolabs, Beverly,
Mass) followed by horseradish peroxidase-linked
goat antirabbit immunoglobulin (1:10,000; Pierce).
Proteins were visualized using chemiluminescent
reagents according to the manufacturer’s instruc-
tions (Supersignal Substrate; Pierce).
Animals and surgical procedure. All animal
procedures were performed with aseptic techniques
in accordance with the Institutional Animal Care
and Use Committee of the University of Pittsburgh.
Adult male Sprague-Dawley rats weighing 400 to
450 g were anesthetized with intraperitoneal sodium
pentobarbital (Nembutal) (45 mg/kg; Abbott
Laboratories, Chicago, Ill) and supplemental inhala-
tional methylfluorane (Metaphane) (Mallinckrodt,
Mundelein, Ill). The left carotid artery was injured
in each animal as previously described.7 Briefly, a 2-
Fr embolectomy catheter (Applied Vascular, Laguna
Hills, Calif) was inserted into the common carotid
artery through the external carotid branch, and
injury was created by inflating the balloon to 5
atmospheres of pressure for 5 minutes. A viral solu-
tion of AdiNOS or AdlacZ (1 × 107 PFU/mL dilut-
ed in Optimem I, similar to 200 µL per carotid) was
then instilled into the common carotid artery for 30
minutes. After the incubation period, the viral solu-
tion was evacuated, the external carotid artery was
ligated, and blood flow through the common
carotid artery was reestablished. The partially selec-
tive iNOS inhibitor L-N6-(1-iminoethyl)-lysine
(NIL; Alexis)20 was administered as a continuous
infusion (1.8 mg/kg per hour) to some animals
using Alzet microosmotic pumps (Alza, Palo Alto,
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Calif) placed in the contralateral external jugular
vein at the time of balloon injury.
Tissue processing and immunohistochem-
istry. Rat carotid arteries were perfused and fixed in
situ with PBS and 2% paraformaldehyde three days
after injury and adenoviral infection. Vessels were
fixed for 1 hour at 4°C in 2% paraformaldehyde and
cryoprotected in 30% sucrose at 4°C overnight.
Vessels were quick-frozen with HistoFreeze-2000
(Fisher, Pittsburgh, Pa), and 7-µm cryosections were
cut at equally spaced intervals along the length of
the vessels. For immunohistochemical staining, sec-
tions were blocked with purified goat immunoglob-
ulin G (50 mg/mL) for 30 minutes, incubated with
a rabbit polyclonal anti-p21 antibody (1:200; Santa
Cruz) for 1 hour, then incubated with the secondary
antibody for 1 hour (goat antirabbit Cy3, 1:3000;
Amersham Corp, Arlington Heights, Ill). The nuclei
were stained with Hoechst 33325 (2 µg/mL in
water) (Sigma) for 30 seconds then coverslipped.
Images were collected with a 40× objective together
with multipass fluorescence cubes to ensure perfect
image registration. The image collection system was
an Olympus Provis microscope (Olympus, Tokyo,
Japan), a high sensitivity, integrating three-chip
color camera (Sony Corp, Park Ridge, NJ), a 
frame grabber board (Coreco Inc, Saint-Laurent,
Quebec, Canada), and Optimus software (Media
Cybernetics, Silver Spring, Md). All images were
collected with the same camera and microscope set-
tings (three frames of integration) with no neutral
density fields.
Statistical analysis. Results are expressed as
mean ± SEM. Differences among groups were ana-
lyzed with one-way analysis of variance with the
Student-Newman-Keuls post-hoc test for all pair-
wise comparisons (SigmaStat; SPSS, Chicago, Ill).
Statistical significance was assumed when P was less
than .05.
RESULTS
Overexpression of iNOS inhibits VSMC prolifera-
tion in a cGMP-independent manner. To study one
mechanism by which iNOS overexpression suppresses
intimal hyperplasia, we examined the capacity of
iNOS/NO to interfere with the cell cycle and cell via-
bility in VSMCs in vitro. High levels of NO2– (P <.001
versus all controls) were produced by RASMCs infect-
ed with AdiNOS, whereas cells infected with AdlacZ
released negligible levels of NO2– (Fig 1, A). Cells
infected with AdiNOS that were treated with the sol-
uble guanylate cyclase inhibitor ODQ released levels
of NO2– similar to untreated AdiNOS-transduced
cells. The release of cGMP was measured in the same
RASMCs to ensure complete inhibition of cGMP pro-
duction by ODQ (Fig 1, B). High levels of cGMP
were produced by AdiNOS-infected cells but not
AdlacZ-infected cells (P <.001). ODQ completely
blocked cGMP release by AdiNOS-treated cells. 3H-
thymidine incorporation into DNA in these RASMCs
was measured to determine the effect of NO produc-
tion on RASMC proliferation (Fig 1, C). Quiescent,
serum-starved RASMCs incorporated little 3H-thymi-
dine. Uninfected and AdlacZ-infected cells incorporat-
ed 3H-thymidine to similar degrees after serum stimu-
lation. However, AdiNOS-infected cells exhibited an
80% reduction in 3H-thymidine incorporation, com-
pared with control groups (P <.001), and this antipro-
liferative effect was completely reversed by the addi-
tion of L-NIO, an irreversible inhibitor of NOS.
However, ODQ failed to prevent NO-mediated inhi-
bition of proliferation, indicating that a cGMP-inde-
pendent mechanism was involved in this process.
Because it is known that RASMCs loose PKG in
later passages,21 we determined whether the early pas-
sage RASMCs used in our studies contained sufficient
cGMP-dependent kinase (PKG) to respond to cGMP.
Western blot analysis for PKG was performed and
compared with the levels of PKG found in three other
common cell lines: Hela (human cervical carcinoma),
U937 (human monocytoid), and HL-60 (human
promyelocytic leukemia). We easily detected PKG
protein in RASMCs, and RASMCs contained higher
levels compared with the other cell lines tested (Fig 1,
D). Additionally, we evaluated the effect of the cGMP
analog, 8-Bromo-cGMP, as well as the PKG activator,
pCPT-cGMP, on RASMC proliferation. Both 8-
Bromo-cGMP and pCPT-cGMP inhibited RASMC
proliferation in a dose-dependent manner (Fig 1, D).
However, the effect observed with 8-Bromo-cGMP
was less dramatic, most likely because of its poor cell
permeability. Our failure to demonstrate a role for
cGMP in the NO-mediated inhibition of proliferation
was not a result of the loss of PKG activity or capaci-
ty to respond to cGMP.
To study the effect of iNOS gene transfer on cell
cycle progression, we measured cellular DNA con-
tent with propidium iodide staining and FACS
analysis (Table). Consistent with studies using NO
donors,22,23 an increase in the relative proportion of
the cells residing in the G0/G1 phase of the cell
cycle was measured in RASMCs expressing iNOS (P
<.001). Additionally, fewer of these cells were found
in the G2/M phase (P <.001). The cell cycle arrest
initiated by iNOS gene transfer was completely
reversed with the NOS inhibitor L-NIO.
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Both cell viability and apoptosis were evaluated
24 hours after iNOS transduction to determine if
iNOS expression and NO synthesis were cytotoxic
to RASMCs (Fig 2, A). With the use of trypan blue
exclusion, RASMCs in all treatment groups were
more than 90% viable. The hypodiploid DNA con-
tent of RASMCs was measured with propidium
iodide staining and FACS analysis. Similar low levels
Fig 1. Inhibition of RASMC proliferation after infection
with AdiNOS in vitro. A, Cultured RASMC were serum
starved for 48 hours, during which time they were infect-
ed with AdiNOS or AdlacZ (MOI = 10). The cells were
then stimulated with 10% FBS, + BH4 (10 µmol/L), ± L-
NIO (1 mmol/L), ± ODQ (40 µmol/L) for 24 hours.
The synthesis of NO was quantitated as NO2– accumula-
tion using the Griess reaction. B, The release of cGMP
was measured with a standard radioimmunoassay. C, 3H-
thymidine incorporation into the DNA was measured as
an estimation of cellular proliferation. D, Additionally,
protein levels of PKG were determined by Western blot
analysis. E, The RASMCs were exposed to the cGMP-ana-
log, 8-Bromo-cGMP, and the PKG activator, pCPT-
cGMP, for 24 hours, and 3H-thymidine incorporation was
measured. Data represent the mean ± SE (n = 3, each
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of hypodiploid DNA were measured in both control
and AdiNOS-infected cells. Additionally, RASMCs
after iNOS gene transfer were cultured in the pres-
ence or absence of BH4 and collected at 24, 48, and
72 hours for DNA fragmentation analysis. An essen-
tial cofactor for all NOS enzymes is BH4, and the
addition of BH4 to RASMCs optimizes NO synthe-
sis after iNOS gene transfer (Fig 2, B). We found no
evidence for DNA fragmentation in any of the treat-
ment groups (Fig 2, C). Thus, NO exposure was not
associated with a detectable increase in VSMC death
in vitro. These results are consistent with previous
publications from our laboratory demonstrating an
absence of toxicity to RASMCs after infection with
AdiNOS using an MOI of 10.7
The transfer of the iNOS gene upregulates 
p21 expression in a cGMP-independent manner.
Exogenously supplied NO donors have been shown
to increase p21 expression in VSMCs.23 We con-
firmed that endogenous NO production after iNOS
gene transfer to VSMCs also upregulated p21.
Untreated cells and cells infected with AdlacZ
expressed low levels of p21 protein after growth
stimulation, as measured by Western blot analysis.
Cells infected with AdlacZ expressed slightly more
p21 than uninfected cells. This minor increase in p21
expression was not associated with a reduction in the
RASMC proliferation rate. However, RASMCs
infected with AdiNOS demonstrated a dramatic
upregulation of p21 protein levels after growth stim-
ulation. This upregulation in p21 was reversed when
NO synthesis was inhibited with L-NIO (Fig 3, A).
Cells infected with AdiNOS were treated with ODQ
to inhibit cGMP, to determine if cGMP mediated
this NO-dependent upregulation of p21 (Fig 3, B).
These cells exhibited the same degree of p21 upreg-
ulation as observed in cells cultured in the absence of
ODQ. These data demonstrate that NO production
in RASMCs induced increases in p21 protein levels
through a cGMP-independent signaling pathway.
Injured rat common carotid arteries were infect-
ed with a low titer of either AdiNOS or AdlacZ 
(2 × 106 PFU per artery) to determine if NO also
upregulates p21 in vivo. Three days after the gene
transfer, animals were sacrificed, and the arteries were
examined with immunohistochemical methods for
p21 protein expression. Uninjured and uninfected
control arteries demonstrated low levels of p21
expression (Fig 4, A). Similarly, injured arteries
infected with AdlacZ expressed low levels of p21 (Fig
4, B). In contrast, AdiNOS-treated vessels stained
strongly for p21 protein in all layers of the vessel wall
(Fig 4, C, D). Continuous infusion of L-NIL, a par-
tially selective iNOS inhibitor, in AdiNOS-treated
animals completely inhibited the effect of iNOS gene
transfer on p21 upregulation (Fig 4, E).
Nitric oxide inhibits VSMC proliferation and
induces p21 expression in a p53-independent manner.
The expression of p21 can be regulated by both
p53-dependent and independent mechanisms.24-27
Because NO has been shown to increase p53 expres-
sion in some cell types,28,29 the role of p53 in NO-
dependent upregulation of p21 in VSMCs was
examined. Cultured aortic VSMCs from p53 –/–
mice were transduced with AdiNOS or AdlacZ at an
MOI of two. As shown in Fig 5, p53 –/– VSMCs
produced NO (Fig 5, A) and released cGMP (Fig 5,
B) in a pattern similar to RASMCs. The iNOS gene
transfer and NO production in p53 –/– murine
VSMCs suppressed cellular proliferation by 80% as
measured by 3H-thymidine incorporation. This
antiproliferative effect was inhibited by L-NIO but
not ODQ (Fig 5, C). We exposed VSMCs from
both wild-type and p53 –/– mice to the NO-donor
SNAP; SNAP inhibited VSMC proliferation in a
concentration- and time-dependent manner in both
cell types (Fig 5, D, E, respectively). Next, we eval-
uated the effect of NO on p21 expression in the p53
–/– VSMCs. Control and AdlacZ-treated p53 –/–
VSMCs demonstrated minimal p21 protein expres-
sion, whereas AdiNOS-infected cells exhibited a
marked increase in p21 protein levels at 24 hours
(Fig 6, A). The upregulation of p21 was inhibited by
L-NIO but was not altered by ODQ (Fig 6, B).
Cell cycle analysis
G0/G1 S G2/M
Control 52.48 ± 0.64 12.77 ± 0.19 23.87 ± 0.43
AdlacZ 49.30 ± 0.21 14.02 ± 1.07 26.70 ± 1.03
AdlacZ + NIO 50.01 ± 0.96 13.65 ± 0.94 26.91 ± 1.39
AdiNOS 61.57 ± 1.16* 13.09 ± 1.10 16.63 ±1.25†
AdiNOS + NIO 48.52 ± 2.61 13.75 ± 0.41 27.17 ± 2.11
*P <.001 versus all other G0/G1 groups.
†P <.001 versus all other G2/M groups.
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These results suggest that NO inhibits proliferation
and upregulates p21 expression in VSMCs through
a p53- and cGMP-independent mechanism.
NO inhibits VSMC proliferation and upregulates
p21 expression through p42/44 mitogen-activated pro-
tein kinase (MAPK). The MAPK signaling cascade
has been shown to be involved in the regulation of
cellular proliferation in VSMCs.30,31 Therefore,
experiments were performed to determine if the
NO-induced inhibition of proliferation and upregu-
lation of p21 were mediated by MAPK activation.
The addition of the p42/44 MAPK inhibitor, PD
98059, to AdiNOS-infected cells partially reversed
the antiproliferative effects of NO (Fig 7, B) without
impairing NO synthesis (Fig 7, A). PD 98059 also
inhibited NO-induced upregulation of p21 (Fig 7,
C). Furthermore, the phosphorylated form of
p42/44 MAPK, as detected by Western blot analysis,
was markedly increased in the iNOS-transduced cells,
and PD98059 inhibited this NO-induced p42/44
MAPK phosphorylation, blocking the activation of
the MAPK signaling cascade (Fig 7, C). Therefore,
NO produced after iNOS gene transfer activates the
p42/44 MAPK signaling cascade, which appears to
Fig 2. Viability of RASMCs after infection with AdiNOS in vitro. A, Viability of RASMCs was
determined by trypan blue exclusion and cell counting of viable cells using a hemocytometer.
Hypodiploid DNA content was measured by propidium iodide staining (50 µg/mL) and
FACS analysis. Data represent the mean ± SE (n = 3, each experiment repeated three times).
B, The RASMCs infected with AdiNOS in the presence and absence of BH4 were collected for
C, DNA fragmentation analysis. At the time of collection, NO2– accumulation was determined
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mediate the inhibition of VSMC proliferation and
the upregulation of p21 expression by NO.
Nitric oxide can inhibit VSMC proliferation inde-
pendent of p21. The VSMCs harvested from both p21
–/– and p21 +/+ mice were exposed to increasing
concentrations of SNAP for different time periods.
Proliferation was inhibited by SNAP, as measured by
3H-thymidine incorporation in both wild-type and
p21 –/– VSMCs in a concentration- and time-depen-
dent manner (Fig 8, A, B, respectively). Not surpris-
ingly, the inhibition of proliferation by NO cannot be
explained by the upregulation of p21 alone.
DISCUSSION
Nitric oxide has been shown to have many vaso-
protective properties. These properties have led to an
increasing interest in NO-based therapies to prevent
vaso-occlusive complications of vascular injury.6,7,32-34
Our laboratory has previously demonstrated that ade-
noviral delivery of the human iNOS cDNA to injured
rat carotid arteries reduced neointima formation by
98%.7 In injured pig iliac arteries, iNOS gene transfer
reduced intimal hyperplasia by 52%.7 Although a
number of mechanisms are involved in NO-mediated
inhibition of intimal hyperplasia, the predominant
mechanism is believed to be through the antiprolif-
erative actions of NO on VSMCs. In this study, NO
produced either after iNOS gene transfer or after
exposure to NO donors inhibited VSMC proliferation
through G0/G1 cell cycle arrest in association with
the upregulation of p21, a cyclin-dependent kinase
(CDK) inhibitor, supporting prior published observa-
tions.22,23 However, the antiproliferative and p21-
upregulating actions of NO were independent of
cGMP, a common signaling pathway used by NO, and
the tumor suppressor p53, one of the main regulatory
factors for p21. Instead, NO exposure was associated
with the phosphorylation and activation of p42/44
MAPK. Inhibiting the activation of this signaling path-
way with PD98059 partially reversed the antiprolifer-
ative effect of NO and completely inhibited p21
upregulation. These data provide proof that NO can
inhibit VSMC proliferation and upregulate p21
expression through the activation of p42/44 MAPK.
However, factors in addition to p21 appear to be
important in the suppression of proliferation by NO.
Nitric oxide is a well-known stimulator of soluble
guanylate cyclase, and it is through this signaling
pathway, in part, that NO mediates vasorelax-
ation.35,36 Exogenous sources of NO, such as the
NO donors SNAP and sodium nitroprusside,
increase cGMP production in VSMCs.35 These NO
donors have also been shown to inhibit VSMC pro-
liferation in vitro in association with a G0/G1 cell
cycle arrest.22,23,37 According to these studies in
which high concentrations of cGMP analogs could
mimic the effect of NO on VSMCs,14,37-39 it has
been suggested that NO inhibits VSMC prolifera-
tion through cGMP-mediated signaling pathways.
Our studies show that inhibition of proliferation
using iNOS gene transfer to RASMCs and murine
VSMCs occurred independent of cGMP. Results
from other published studies using inhibitors to
cGMP-dependent protein kinase (PKG) during
exposure to NO-donors have been conflicting.14,23
By inhibiting cGMP function, we provide evidence
that cGMP is not a major contributor to the
antiproliferative actions of NO in cultured rodent
A
B
Fig 3. The iNOS gene transfer increases p21 protein
expression in RASMCs. Cultured RASMCs were infected
with AdiNOS or AdlacZ (MOI = 10). A, Whole cell
extracts of RASMCs treated with 10% FBS, + BH4 (10
µmol/L), ± L-NIO (1 mmol/L) were subjected to
Western blot analysis for p21 protein expression 24 hours
after stimulation with FBS. B, Whole cell extracts of
RASMCs treated with 10% FBS, + BH4 (10 µmol/L), ±
ODQ (40 µmol/L) were subjected to Western blot analy-
sis for p21 protein expression 24 hours after stimulation
with FBS. Data are representative of four similar experi-
ments.
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VSMCs. The levels of PKG expression decrease in
VSMCs cultured through several passages,21 and
this may explain the observation that PKG inhibitors
do not always prevent the antiproliferative effects of
NO.23 In our study, we used early passage cells (pas-
sage 3-8). Furthermore, we demonstrated that the
early passage VSMCs used in our studies retained
high levels of PKG. Treatment of the cells with 8-
Bromo-cGMP as well as the PKG activator, pCPT-
cGMP, inhibited VSMC proliferation, indicating
that the cells used in our studies responded to
cGMP. Although NO can stimulate the release of
cGMP and cGMP can inhibit VSMC proliferation,
our data indicate that alternate signaling pathways
may also play a significant role in mediating NO-
induced inhibition of VSMC proliferation. It is not
surprising that NO may be able to exert its effects
through cGMP-independent pathways, because this
Fig 4. Immunohistochemistry for p21 protein expression in rat carotid arteries after balloon-
induced injury and infection with AdiNOS. Rat common carotid arteries that are injured and
infected with AdiNOS or AdlacZ were harvested at day 3 by in situ perfusion and immersion
fixation in 2% paraformaldehyde. Some animals received continuous infusion of NIL (1.8
mg/kg per hour) by means of an Alzet microosmotic pump. After cryopreservation, seven µm
sections were probed for p21 protein expression using a rabbit polyclonal anti-p21 antibody
(1:200). Protein binding by the anti-p21 antibody was visualized with a secondary antibody
that had a fluorescent tag (1:3000) to show the p21 expression (red) in the carotid arteries.
Final image magnification is 400×. The elastic laminae (green) were visualized by their inher-
ent autofluorescence. A, Uninjured, uninfected carotid artery; B, injured and infected with
AdlacZ; C, injured and infected with AdiNOS; D, injured and infected with AdiNOS. Nuclei
(blue) were additionally visualized by counterstaining with Hoechst 33325. Cells staining pos-
itive for p21 (red) superimposed on the blue nuclei will appear pink, confirming that the p21
expression was in cells. E, Injured and infected with AdiNOS in the presence of continuous
infusion of the NOS inhibitor NIL; F, injured and infected with AdiNOS. Received no anti-
p21 antibody (negative control). For each experimental group, n = 4.
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has been suggested in other cell types40-45 and with
other physiologic effects mediated by NO in
VSMCs.22,46
Cyclins, CDKs and CDK inhibitors govern the
cell cycle. The CDK inhibitors are naturally occur-
ring cell cycle inhibitors that function by binding to
cyclins, CDKs, or the complex of the two and pre-
venting their activation.47,48 A member of the
Kip/Cip family is p21, and it has been shown to
inhibit cdc2, CDK2, CDK4, CDK6, cyclin D, cyclin
E, cyclin A, and cyclin B.49 Because it is regarded as
a universal inhibitor of the cell cycle, the role of p21
in the NO-mediated antiproliferative effects was
evaluated. Synthesis of NO after iNOS gene transfer
Fig 5. The iNOS gene transfer inhibited proliferation in
p53 –/– VSMCs in vitro. A, Cultured aortic p53 –/–
VSMCs were infected with AdiNOS or AdlacZ (MOI = 2)
and stimulated with 10% FBS, + BH4 (10 µmol/L), ± L-
NIO (1 mmol/L), ± ODQ (40 µmol/L) for 24 hours.
The NO synthesis was quantitated as NO2– accumulation
using the Griess reaction. B, The release of cGMP was
measured with a standard radioimmunoassay. C, 3H-
thymidine incorporation into the DNA was measured as
an estimation of cellular proliferation. D, p53 –/– and p53
+/+ VSMCs were exposed to increasing concentrations of
SNAP for 48 hours. E, p53 –/– and p53 +/+ VSMCs
were exposed to SNAP (0.5 mmol/L) for different time
periods. Data represent the mean ± SE (n = 3, each exper-
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resulted in the upregulation of p21, which support-
ed previously published data from Ishida et al,23
who used NO donors to increase p21 expression.
However, we found that the upregulation of p21 by
iNOS/NO in cultured VSMCs was independent of
cGMP. Additionally, we found that gene transfer of
iNOS to injured rat carotid arteries in vivo also
resulted in p21 upregulation when examined three
days after injury. Yang et al50 reported that p21 was
upregulated after injury in the porcine vasculature
beginning on day 7, peaking at day 21, and disap-
pearing by day 60. This pattern of expression was
inversely related to the rates of maximal proliferation
observed in the neointima and media of the vessel
wall. To demonstrate the significance of p21 expres-
sion in the vascular injury response, they overex-
pressed p21 at the time of arterial injury through
adenoviral gene transfer and found that early over-
expression of p21 resulted in a reduction of the
neointima formation. Increasing p21 expression may
be one mechanism by which NO inhibits VSMC
proliferation. However, we demonstrated that cells
incapable of p21 expression still exhibited reduced
proliferation when exposed to NO, indicating that
other mechanisms are operative. In support of this,
we have found that NO also upregulates two of the
other members of the Kip/Cip family of CDK
inhibitors, p27 and p57. However, the degree of the
upregulation for these two proteins was not as dra-
matic as seen for p21 (Kibbe et al, unpublished data,
1998). This demonstrates the redundant nature of
cell cycle regulation. Namely, there are multiple lev-
els of regulation, and many different regulatory pro-
teins may function together toward a unified goal.
This appears to be the case with NO in its ability to
inhibit VSMC proliferation, because NO can affect
the cell cycle at multiple levels by regulating
cyclins,23 CDKs 23, and CDK inhibitors.
Nitric oxide has been shown to induce p53
expression in several human tumor cell lines and
murine fibroblasts.28,29 One downstream effect of
p53 expression is the induction of p21.51 Originally,
p21 was described as a transcriptional target of p53
that mediated the tumor suppressive properties of
p53 and is thought to be essential in regulating p53-
induced cell cycle arrest.24 One role of p21 is to ini-
tiate cell cycle arrest in cells that have sustained
genomic injury, thereby permitting DNA repair or
committing the cell to apoptosis. Recently however,
cell cycle arrest by a variety of stimuli has been
shown to be mediated by p21 in cell types deficient
in p53 expression.26,27,52-55 Our results show that
not only is p21 upregulation independent of p53
but that p53 is not essential for the NO-mediated
antiproliferative effects.
Recently, NO-related species have been reported
to activate the p42/44 MAPK pathway in human
Jurkat cells, rat mesangial cells, rat hippocampal
cells, and microvascular endothelial cells.56-60
Additionally, Ras has been reported to increase p21
expression through the activation of p42/44
MAPK.61 Our results implicate activation of p42/44
by NO as a dominant signaling pathway for both the
inhibition of proliferation and induction of p21. We
evaluated only the 24-hour time point, but our
A
B
Fig 6. iNOS gene transfer increases p21 protein expres-
sion in p53 –/– VSMCs. Cultured aortic p53 –/– VSMCs
were infected with AdiNOS or AdlacZ (MOI = 2). A,
Whole cell extracts of the p53 –/– VSMCs treated with
10% FBS, + BH4 (10 µmol/L) and ± L-NIO (1 mmol/L)
were subjected to Western blot analysis for p21 protein
expression 24 hours after stimulation with FBS. B, Whole
cell extracts of p53 –/– VSMCs treated with 10% FBS, +
BH4 (10 µmol/L), ± ODQ (40 µmol/L) were subjected
to Western blot analysis for p21 protein expression 24
hours after stimulation with FBS. Data are representative
of four similar experiments.
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results are consistent with the findings of Callsen et
al,57 who found that endogenous and exogenous
sources of NO induced both an early and late acti-
vation of the p42/44 MAPK pathway in rat mesan-
gial cells. Proliferation is stimulated by NO-mediat-
ed p42/44 activation in endothelial cells.59 The rea-
son for these opposing responses to the same
stimulus/signaling pathway in two different cell
types is unclear but underscores the diverse and cell
type-specific actions of NO. It is perhaps not sur-
prising that a molecule such as NO that functions to
promote vessel wall homeostasis would promote
endothelial cell growth to support reendothelializa-
tion while simultaneously limiting VSMC over-
growth.
Therapies that are NO-based hold great promise
as methods to limit VSMC overgrowth in a number
of clinical conditions. Our previous work7,8 and these
current studies examining the signaling pathways used
by NO in VSMCs to upregulate p21 expression and
Fig 7. Activation of the p42/44 MAPK by iNOS gene transfer mediates the antiproliferative
and p21 stimulatory effects of NO in RASMCs in vitro. Cultured RASMCs were infected with
AdiNOS or AdlacZ (MOI = 10). The cells were stimulated with 10% FBS, + BH4 (10
µmol/L), ± PD 98059 (20 µmol/L) for 24 hours. A, The NO synthesis was quantitated as
NO2– accumulation using the Griess reaction. B, 3H-thymidine incorporation into DNA was
measured as an estimation of cellular proliferation. Data represent the mean ± SE (n = 3, each
experiment repeated four times). C, Whole cell extracts of RASMCs treated with 10% FBS, +
BH4 (10 µmol/L), ± PD 98059 (50 µmol/L) were subjected to Western blot analysis for p21,
phosphorylated p42/44, and p42 protein expression 24 hours after stimulation with FBS.
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inhibit proliferation provide significant insight into
one of the mechanisms by which NO may limit inti-
mal hyperplasia in vivo. Understanding these mecha-
nisms may help to provide different approaches to
pharmacologically target vascular disease processes.
We thank Sean Alber, MS, and Ciprian Almonte, BS,
from the University of Pittsburgh Center for Biologic
Imaging for their help with image collection.
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